

# Implantica presents the fourth quarter 2022 on February 17 at 15:00 CET

Implantica AG (publ) invites investors to a presentation of the fourth quarter 2022 at 15:00 CET on February 17. The interim report for the fourth quarter will be published at 8:00 a.m. CET on the same day.

The presentation will be in English via an audiocast with teleconference:

Conference call dial-in:

- Sweden: +46 8 505 163 86
- United Kingdom: +44 20 319 84884
- United States: +1-412-317-6300

Pin code: 2209644#

Webcast:

- <http://ir.financialhearings.com/implantica-q4-2022>

Speakers:

- CEO Peter Forsell
- CFO Andreas Öhrnberg
- Chief Corporate Affairs Officer Nicole Pehrsson

## For further information, please contact:

Nicole Pehrsson, Investor Relations  
Telephone (CH): +41 (0)79 335 09 49  
[nicole.pehrsson@implantica.com](mailto:nicole.pehrsson@implantica.com)

Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.

The company's Certified Adviser is FNCA Sweden AB, [info@fnca.se](mailto:info@fnca.se)

*The information was sent for publication, through the agency of the contact person set out above, on February 13, 2023 at 09:30 a.m. CET.*

## About Implantica

Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising

platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit [www.implantica.com](http://www.implantica.com) for further information.